View Older Stories View More Recent Stories

Aug 9, 2021 09:15AM ENHERTU® (fam-trastuzumab deruxtecan-nxki) significantly improved progression-free survival in DESTINY-Breast03 head-to-head trial vs. trastuzumab emtansine (T-DM1) in patients with HER2
Aug 2, 2021 07:14AM AstraZeneca (AZN) Announces SAPHNELO Approved in the US for Moderate to Severe Systemic Lupus Erythematosus
Aug 2, 2021 07:00AM SAPHNELO (anifrolumab) Approved in the US for Moderate to Severe Systemic Lupus Erythematosus
Jul 27, 2021 07:11AM Regeneron (REGN), AstraZeneca (AZN) to Research, Develop and Commercialize New Small Molecule Medicines for Obesity
Jul 23, 2021 07:03AM AstraZeneca (AZN) Announces BYDUREON BCise Approved in the US for Treatment of Type 2 Diabetes in Pediatric Patients Ages 10 Years and Older
Jul 23, 2021 07:00AM BYDUREON BCise (exenatide extended-release) Approved in the US for the Treatment of Type 2 Diabetes in Pediatric Patients Ages 10 Years and Older
Jul 8, 2021 08:06AM F-Star Therapeutics (FSTX) Enters into Exclusive Licensing Agreement with AstraZeneca for Novel STING Inhibitors
Jul 8, 2021 08:00AM F-star Therapeutics Enters into Exclusive Licensing Agreement with AstraZeneca for Novel STING Inhibitors
Jul 8, 2021 08:00AM F-star Therapeutics Enters into Exclusive Licensing Agreement with AstraZeneca for Novel STING Inhibitors
Jul 8, 2021 07:00AM Tezepelumab Regulatory Submission Accepted and Granted FDA Priority Review in the US for the Treatment of Patients with Asthma
Jun 25, 2021 12:11PM AstraZeneca (AZN) Phase III pivotal trial of once weekly exenatide in adolescents aged 10–17 shows benefit for the treatment of type 2 diabetes
Jun 25, 2021 12:09PM Phase III pivotal trial of once weekly exenatide in adolescents aged 10–17 shows benefit for the treatment of type 2 diabetes
Jun 7, 2021 07:00AM CALQUENCE Demonstrated Fewer Incidences of Atrial Fibrillation Versus Ibrutinib in Previously Treated Patients With Chronic Lymphocytic Leukemia and Sustained Patient Benefit at Four Years in the Fron
Jun 4, 2021 07:03AM AstraZeneca (AZN) Announces IMFINZI Demonstrated Unprecedented Survival in Unresectable Stage III Lung Cancer With 43% Of Patients Surviving Five Years
Jun 4, 2021 07:00AM IMFINZI Demonstrated Unprecedented Survival in Unresectable Stage III Lung Cancer With 43% Of Patients Surviving Five Years
Jun 3, 2021 05:12PM AstraZeneca (AZN) Announces LYNPARZA reduced risk of cancer recurrence by 42% in adjuvant treatment of patients with germline BRCA-mutated high-risk early breast cancer in OlympiA Phase III trial
Jun 3, 2021 05:00PM LYNPARZA® (olaparib) reduced the risk of cancer recurrence by 42% in the adjuvant treatment of patients with germline BRCA-mutated high-risk early breast cancer in OlympiA Phase III trial
May 19, 2021 05:05PM AstraZeneca ASCO 2021 Data Support Ambition to Revolutionize Cancer Outcomes by Treating Earlier and Transforming the Patient Experience
May 19, 2021 10:01AM New FASENRA® Data From the MELTEMI Extension Trial Confirm Long-Term Safety and Efficacy in Severe Eosinophilic Asthma for up to Five Years
May 13, 2021 07:15AM AstraZeneca (AZN), Amgen (AMGN) New Tezepelumab Data Continue to Strengthen Profile for a Broad Population of Severe Asthma Patients
May 13, 2021 07:00AM New Tezepelumab Data Continue to Strengthen Profile for a Broad Population of Severe Asthma Patients
May 10, 2021 09:02AM Amgen (AMGN) Announces Tezepelumab Biologics License Application Submitted To U.S. FDA
May 10, 2021 09:00AM Amgen Announces Tezepelumab Biologics License Application Submitted To U.S. FDA
May 7, 2021 07:15AM AstraZeneca's (AZN) IMFINZI and tremelimumab With Chemotherapy Demonstrated OS Benefit in POSEIDON Trial for 1st-line Stage IV NSLC
May 7, 2021 07:00AM IMFINZI and tremelimumab With Chemotherapy Demonstrated Overall Survival Benefit in POSEIDON Trial for 1st-line Stage IV Non-small Cell Lung Cancer
Apr 30, 2021 06:20PM FARXIGA Approved in the US for the Treatment of Chronic Kidney Disease in Patients at Risk of Progression With and Without Type 2 Diabetes
Apr 30, 2021 09:28AM Pre-Open Stock Movers 04/30: (LAUR) (WDC) (TEAM) Higher; (MVIS) (ARDX) (TWTR) Lower (more...)
Apr 20, 2021 04:01AM ENHERTU® ▼ (TRASTUZUMAB DERUXTECAN) NOW AVAILABLE VIA THE CANCER DRUGS FUND FOR THE TREATMENT OF HER2 POSITIVE METASTATIC BREAST CANCER
Apr 14, 2021 08:30AM Veracyte Announces Key Milestone in Companion Diagnostics Program With Acerta Pharma Using LymphMark Lymphoma Subtyping Test
Apr 6, 2021 07:00AM AstraZeneca Announces Collaboration with Massachusetts General Hospital to Accelerate Digital Health Solutions
Mar 25, 2021 06:16AM AstraZeneca (AZN) announces 76% vaccine efficacy against symptomatic COVID-19
Mar 24, 2021 08:53PM AZD1222 US Phase III Primary Analysis Confirms Safety and Efficacy
Mar 22, 2021 07:00AM AZD1222 US Phase III Trial Met Primary Efficacy Endpoint in Preventing COVID-19 at Interim Analysis
Feb 26, 2021 09:07AM Amgen (AMGN), AstraZeneca (AZN) Say Tezepelumab Is First Biologic To Significantly Reduce Exacerbations In Broad Population Of Patients With Severe, Uncontrolled Asthma
Feb 26, 2021 09:00AM Tezepelumab Is the First Biologic to Consistently and Significantly Reduce Exacerbations in Broad Population of Severe Asthma Patients
Feb 17, 2021 06:59AM AstraZeneca (AZN), Merck (MRK) Announce IDMC Concludes OlympiA Trial of LYNPARZA Crossed Superiority Boundary for Invasive Disease-Free Survival vs. Placebo at Planned Interim Analysis
Feb 17, 2021 06:55AM IDMC has Concluded that OlympiA Trial of LYNPARZA® (olaparib) Crossed Superiority Boundary for Invasive Disease-free Survival Vs. Placebo at Planned Interim Analysis
Feb 16, 2021 02:00AM ENHERTU® ▼ (TRASTUZUMAB DERUXTECAN) AUTHORISED IN THE UK FOR THE TREATMENT OF HER2 POSITIVE METASTATIC BREAST CANCER
Jan 29, 2021 07:00AM TAGRISSO Extended Disease-Free Survival Regardless of Prior Adjuvant Chemotherapy in Early-Stage EGFR-Mutated Lung Cancer
Jan 25, 2021 07:05AM AstraZeneca (AZN) Announces CALQUENCE Met Primary Efficacy Endpoint in Head-to-Head Trial Against ibrutinib in Chronic Lymphocytic Leukemia
Jan 25, 2021 07:00AM CALQUENCE Met Primary Efficacy Endpoint in Head-to-Head Trial Against ibrutinib in Chronic Lymphocytic Leukemia
Jan 18, 2021 07:00AM ENHERTU® (fam-trastuzumab deruxtecan-nxki) Approved in the US for the Treatment of Patients with Previously Treated HER2-Positive Advanced Gastric Cancer
Jan 13, 2021 09:00AM AstraZeneca to Showcase Transformative Data Across Diverse Pipeline at World Conference on Lung Cancer
Jan 11, 2021 04:13PM Adaptive Biotechnologies (ADPT) to Collaborate with AstraZeneca (AZN) in Mapping the Immune Response to Cancer Antigens to Potentially Inform the Development of Novel Diagnostics and Therapeutics
Jan 11, 2021 04:01PM Adaptive Biotechnologies to Collaborate with AstraZeneca in Mapping the Immune Response to Cancer Antigens to Potentially Inform the Development of Novel Diagnostics and Therapeutics
Jan 6, 2021 07:00AM FARXIGA Granted Priority Review in the US for the Treatment of Patients With Chronic Kidney Disease
Dec 28, 2020 06:47AM AstraZeneca (AZN), Merck (MRK) Announce LYNPARZA Granted Three New Approvals in Japan
Dec 22, 2020 06:10AM Amgen (AMGN), AstraZeneca (AZN) Report SOURCE Phase 3 Trial For Tezepelumab Did Not Meet Primary Endpoint in
Dec 22, 2020 06:10AM Amgen (AMGN), AstraZeneca (AZN) Report SOURCE Phase 3 Trial For Tezepelumab Did Not Meet Primary Endpoint in
Dec 21, 2020 07:00AM TAGRISSO Approved in the US for the Adjuvant Treatment of Patients With Early-Stage EGFR-mutated Lung Cancer
View More Recent Stories View Older Stories